Picture of Sun Pharmaceutical Industries logo

SUNPHARMA — Sun Pharmaceutical Industries News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareConservativeLarge CapHigh Flyer

Street View: India's Sun Pharma rises after U.S. tariff reprieve tied to drug-pricing deal

BUZZ-Street View: India's Sun Pharma rises after U.S. tariff reprieve tied to drug-pricing deal

** Sun Pharmaceutical Industries SUN.NS secures two-year delay to potential U.S. tariffs on its innovative drugs by agreeing to offer discounted medicines to Medicaid patients

** Shares of the company were up 0.5% to 1,938 rupees


TARIFF REPRIEVE OUTWEIGHING MEDICAID PRICING IMPACT


** Bernstein ("Outperform," PT: 2,235 rupees) says agreement removes a near-term margin overhang and supports Sun's innovation-led pipeline through global partnerships

** HSBC Global Investment Research ("Buy," PT: 2,120 rupees)sees improving profitability of Sun's innovative medicines portfolio boosting operating leverage and consolidated margins

** Kotak Institutional Equities ("Add," PT: 2,150 rupees) says lower Medicaid pricing could weigh on EPS, but Medicare exclusion and tariff reprieve make the deal marginally positive

** ICICI Securities ("Add," PT: 2,100 rupees) says tariff protection safeguards Sun's specialty portfolio, though similar protection is needed for Organon after the acquisition

"The deal may also help Sun win M&A deals, especially for companies and assets at risk of being hit by tariffs," - ICICI


(Reporting by Abhinav Parmar in Bengaluru)

((Abhinav.Parmar@thomsonreuters.com;))

Recent news on Sun Pharmaceutical Industries

See all news